Androgen receptor-mediated pharmacogenomic expression quantitative trait loci: implications for breast cancer response to AR-targeting therapy
Background Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The androgen receptor (AR) is also expressed in the vast majority (80–90%) of ERα-positive tumors. AR-targeting drugs are not used in clinical practice,...
Uloženo v:
| Vydáno v: | Breast cancer research : BCR Ročník 26; číslo 1; s. 111 - 14 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
04.07.2024
BioMed Central Ltd Springer Nature B.V BMC |
| Témata: | |
| ISSN: | 1465-542X, 1465-5411, 1465-542X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The androgen receptor (AR) is also expressed in the vast majority (80–90%) of ERα-positive tumors. AR-targeting drugs are not used in clinical practice, but have been evaluated in multiple trials and preclinical studies.
Methods
We performed a genome-wide study to identify hormone/drug-induced single nucleotide polymorphism (SNP) genotype - dependent gene-expression, known as PGx-eQTL, mediated by either an AR agonist (dihydrotestosterone) or a partial antagonist (enzalutamide), utilizing a previously well characterized lymphoblastic cell line panel. The association of the identified SNPs-gene pairs with breast cancer phenotypes were then examined using three genome-wide association (GWAS) studies that we have published and other studies from the GWAS catalog.
Results
We identified 13 DHT-mediated PGx-eQTL loci and 23 Enz-mediated PGx-eQTL loci that were associated with breast cancer outcomes post ER antagonist or aromatase inhibitors (AI) treatment, or with pharmacodynamic (PD) effects of AIs. An additional 30 loci were found to be associated with cancer risk and sex-hormone binding globulin levels. The top loci involved the genes IDH2 and TMEM9, the expression of which were suppressed by DHT in a PGx-eQTL SNP genotype-dependent manner. Both of these genes were overexpressed in breast cancer and were associated with a poorer prognosis. Therefore, suppression of these genes by AR agonists may benefit patients with minor allele genotypes for these SNPs.
Conclusions
We identified AR-related PGx-eQTL SNP-gene pairs that were associated with risks, outcomes and PD effects of endocrine therapy that may provide potential biomarkers for individualized treatment of breast cancer. |
|---|---|
| AbstractList | BackgroundEndocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The androgen receptor (AR) is also expressed in the vast majority (80–90%) of ERα-positive tumors. AR-targeting drugs are not used in clinical practice, but have been evaluated in multiple trials and preclinical studies.MethodsWe performed a genome-wide study to identify hormone/drug-induced single nucleotide polymorphism (SNP) genotype - dependent gene-expression, known as PGx-eQTL, mediated by either an AR agonist (dihydrotestosterone) or a partial antagonist (enzalutamide), utilizing a previously well characterized lymphoblastic cell line panel. The association of the identified SNPs-gene pairs with breast cancer phenotypes were then examined using three genome-wide association (GWAS) studies that we have published and other studies from the GWAS catalog.ResultsWe identified 13 DHT-mediated PGx-eQTL loci and 23 Enz-mediated PGx-eQTL loci that were associated with breast cancer outcomes post ER antagonist or aromatase inhibitors (AI) treatment, or with pharmacodynamic (PD) effects of AIs. An additional 30 loci were found to be associated with cancer risk and sex-hormone binding globulin levels. The top loci involved the genes IDH2 and TMEM9, the expression of which were suppressed by DHT in a PGx-eQTL SNP genotype-dependent manner. Both of these genes were overexpressed in breast cancer and were associated with a poorer prognosis. Therefore, suppression of these genes by AR agonists may benefit patients with minor allele genotypes for these SNPs.ConclusionsWe identified AR-related PGx-eQTL SNP-gene pairs that were associated with risks, outcomes and PD effects of endocrine therapy that may provide potential biomarkers for individualized treatment of breast cancer. Background Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The androgen receptor (AR) is also expressed in the vast majority (80–90%) of ERα-positive tumors. AR-targeting drugs are not used in clinical practice, but have been evaluated in multiple trials and preclinical studies. Methods We performed a genome-wide study to identify hormone/drug-induced single nucleotide polymorphism (SNP) genotype - dependent gene-expression, known as PGx-eQTL, mediated by either an AR agonist (dihydrotestosterone) or a partial antagonist (enzalutamide), utilizing a previously well characterized lymphoblastic cell line panel. The association of the identified SNPs-gene pairs with breast cancer phenotypes were then examined using three genome-wide association (GWAS) studies that we have published and other studies from the GWAS catalog. Results We identified 13 DHT-mediated PGx-eQTL loci and 23 Enz-mediated PGx-eQTL loci that were associated with breast cancer outcomes post ER antagonist or aromatase inhibitors (AI) treatment, or with pharmacodynamic (PD) effects of AIs. An additional 30 loci were found to be associated with cancer risk and sex-hormone binding globulin levels. The top loci involved the genes IDH2 and TMEM9, the expression of which were suppressed by DHT in a PGx-eQTL SNP genotype-dependent manner. Both of these genes were overexpressed in breast cancer and were associated with a poorer prognosis. Therefore, suppression of these genes by AR agonists may benefit patients with minor allele genotypes for these SNPs. Conclusions We identified AR-related PGx-eQTL SNP-gene pairs that were associated with risks, outcomes and PD effects of endocrine therapy that may provide potential biomarkers for individualized treatment of breast cancer. Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The androgen receptor (AR) is also expressed in the vast majority (80-90%) of ERα-positive tumors. AR-targeting drugs are not used in clinical practice, but have been evaluated in multiple trials and preclinical studies.BACKGROUNDEndocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The androgen receptor (AR) is also expressed in the vast majority (80-90%) of ERα-positive tumors. AR-targeting drugs are not used in clinical practice, but have been evaluated in multiple trials and preclinical studies.We performed a genome-wide study to identify hormone/drug-induced single nucleotide polymorphism (SNP) genotype - dependent gene-expression, known as PGx-eQTL, mediated by either an AR agonist (dihydrotestosterone) or a partial antagonist (enzalutamide), utilizing a previously well characterized lymphoblastic cell line panel. The association of the identified SNPs-gene pairs with breast cancer phenotypes were then examined using three genome-wide association (GWAS) studies that we have published and other studies from the GWAS catalog.METHODSWe performed a genome-wide study to identify hormone/drug-induced single nucleotide polymorphism (SNP) genotype - dependent gene-expression, known as PGx-eQTL, mediated by either an AR agonist (dihydrotestosterone) or a partial antagonist (enzalutamide), utilizing a previously well characterized lymphoblastic cell line panel. The association of the identified SNPs-gene pairs with breast cancer phenotypes were then examined using three genome-wide association (GWAS) studies that we have published and other studies from the GWAS catalog.We identified 13 DHT-mediated PGx-eQTL loci and 23 Enz-mediated PGx-eQTL loci that were associated with breast cancer outcomes post ER antagonist or aromatase inhibitors (AI) treatment, or with pharmacodynamic (PD) effects of AIs. An additional 30 loci were found to be associated with cancer risk and sex-hormone binding globulin levels. The top loci involved the genes IDH2 and TMEM9, the expression of which were suppressed by DHT in a PGx-eQTL SNP genotype-dependent manner. Both of these genes were overexpressed in breast cancer and were associated with a poorer prognosis. Therefore, suppression of these genes by AR agonists may benefit patients with minor allele genotypes for these SNPs.RESULTSWe identified 13 DHT-mediated PGx-eQTL loci and 23 Enz-mediated PGx-eQTL loci that were associated with breast cancer outcomes post ER antagonist or aromatase inhibitors (AI) treatment, or with pharmacodynamic (PD) effects of AIs. An additional 30 loci were found to be associated with cancer risk and sex-hormone binding globulin levels. The top loci involved the genes IDH2 and TMEM9, the expression of which were suppressed by DHT in a PGx-eQTL SNP genotype-dependent manner. Both of these genes were overexpressed in breast cancer and were associated with a poorer prognosis. Therefore, suppression of these genes by AR agonists may benefit patients with minor allele genotypes for these SNPs.We identified AR-related PGx-eQTL SNP-gene pairs that were associated with risks, outcomes and PD effects of endocrine therapy that may provide potential biomarkers for individualized treatment of breast cancer.CONCLUSIONSWe identified AR-related PGx-eQTL SNP-gene pairs that were associated with risks, outcomes and PD effects of endocrine therapy that may provide potential biomarkers for individualized treatment of breast cancer. Abstract Background Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The androgen receptor (AR) is also expressed in the vast majority (80–90%) of ERα-positive tumors. AR-targeting drugs are not used in clinical practice, but have been evaluated in multiple trials and preclinical studies. Methods We performed a genome-wide study to identify hormone/drug-induced single nucleotide polymorphism (SNP) genotype - dependent gene-expression, known as PGx-eQTL, mediated by either an AR agonist (dihydrotestosterone) or a partial antagonist (enzalutamide), utilizing a previously well characterized lymphoblastic cell line panel. The association of the identified SNPs-gene pairs with breast cancer phenotypes were then examined using three genome-wide association (GWAS) studies that we have published and other studies from the GWAS catalog. Results We identified 13 DHT-mediated PGx-eQTL loci and 23 Enz-mediated PGx-eQTL loci that were associated with breast cancer outcomes post ER antagonist or aromatase inhibitors (AI) treatment, or with pharmacodynamic (PD) effects of AIs. An additional 30 loci were found to be associated with cancer risk and sex-hormone binding globulin levels. The top loci involved the genes IDH2 and TMEM9, the expression of which were suppressed by DHT in a PGx-eQTL SNP genotype-dependent manner. Both of these genes were overexpressed in breast cancer and were associated with a poorer prognosis. Therefore, suppression of these genes by AR agonists may benefit patients with minor allele genotypes for these SNPs. Conclusions We identified AR-related PGx-eQTL SNP-gene pairs that were associated with risks, outcomes and PD effects of endocrine therapy that may provide potential biomarkers for individualized treatment of breast cancer. Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The androgen receptor (AR) is also expressed in the vast majority (80-90%) of ERα-positive tumors. AR-targeting drugs are not used in clinical practice, but have been evaluated in multiple trials and preclinical studies. We performed a genome-wide study to identify hormone/drug-induced single nucleotide polymorphism (SNP) genotype - dependent gene-expression, known as PGx-eQTL, mediated by either an AR agonist (dihydrotestosterone) or a partial antagonist (enzalutamide), utilizing a previously well characterized lymphoblastic cell line panel. The association of the identified SNPs-gene pairs with breast cancer phenotypes were then examined using three genome-wide association (GWAS) studies that we have published and other studies from the GWAS catalog. We identified 13 DHT-mediated PGx-eQTL loci and 23 Enz-mediated PGx-eQTL loci that were associated with breast cancer outcomes post ER antagonist or aromatase inhibitors (AI) treatment, or with pharmacodynamic (PD) effects of AIs. An additional 30 loci were found to be associated with cancer risk and sex-hormone binding globulin levels. The top loci involved the genes IDH2 and TMEM9, the expression of which were suppressed by DHT in a PGx-eQTL SNP genotype-dependent manner. Both of these genes were overexpressed in breast cancer and were associated with a poorer prognosis. Therefore, suppression of these genes by AR agonists may benefit patients with minor allele genotypes for these SNPs. We identified AR-related PGx-eQTL SNP-gene pairs that were associated with risks, outcomes and PD effects of endocrine therapy that may provide potential biomarkers for individualized treatment of breast cancer. Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor [alpha] (ER[alpha]). The androgen receptor (AR) is also expressed in the vast majority (80-90%) of ER[alpha]-positive tumors. AR-targeting drugs are not used in clinical practice, but have been evaluated in multiple trials and preclinical studies. We performed a genome-wide study to identify hormone/drug-induced single nucleotide polymorphism (SNP) genotype - dependent gene-expression, known as PGx-eQTL, mediated by either an AR agonist (dihydrotestosterone) or a partial antagonist (enzalutamide), utilizing a previously well characterized lymphoblastic cell line panel. The association of the identified SNPs-gene pairs with breast cancer phenotypes were then examined using three genome-wide association (GWAS) studies that we have published and other studies from the GWAS catalog. We identified 13 DHT-mediated PGx-eQTL loci and 23 Enz-mediated PGx-eQTL loci that were associated with breast cancer outcomes post ER antagonist or aromatase inhibitors (AI) treatment, or with pharmacodynamic (PD) effects of AIs. An additional 30 loci were found to be associated with cancer risk and sex-hormone binding globulin levels. The top loci involved the genes IDH2 and TMEM9, the expression of which were suppressed by DHT in a PGx-eQTL SNP genotype-dependent manner. Both of these genes were overexpressed in breast cancer and were associated with a poorer prognosis. Therefore, suppression of these genes by AR agonists may benefit patients with minor allele genotypes for these SNPs. We identified AR-related PGx-eQTL SNP-gene pairs that were associated with risks, outcomes and PD effects of endocrine therapy that may provide potential biomarkers for individualized treatment of breast cancer. Background Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor [alpha] (ER[alpha]). The androgen receptor (AR) is also expressed in the vast majority (80-90%) of ER[alpha]-positive tumors. AR-targeting drugs are not used in clinical practice, but have been evaluated in multiple trials and preclinical studies. Methods We performed a genome-wide study to identify hormone/drug-induced single nucleotide polymorphism (SNP) genotype - dependent gene-expression, known as PGx-eQTL, mediated by either an AR agonist (dihydrotestosterone) or a partial antagonist (enzalutamide), utilizing a previously well characterized lymphoblastic cell line panel. The association of the identified SNPs-gene pairs with breast cancer phenotypes were then examined using three genome-wide association (GWAS) studies that we have published and other studies from the GWAS catalog. Results We identified 13 DHT-mediated PGx-eQTL loci and 23 Enz-mediated PGx-eQTL loci that were associated with breast cancer outcomes post ER antagonist or aromatase inhibitors (AI) treatment, or with pharmacodynamic (PD) effects of AIs. An additional 30 loci were found to be associated with cancer risk and sex-hormone binding globulin levels. The top loci involved the genes IDH2 and TMEM9, the expression of which were suppressed by DHT in a PGx-eQTL SNP genotype-dependent manner. Both of these genes were overexpressed in breast cancer and were associated with a poorer prognosis. Therefore, suppression of these genes by AR agonists may benefit patients with minor allele genotypes for these SNPs. Conclusions We identified AR-related PGx-eQTL SNP-gene pairs that were associated with risks, outcomes and PD effects of endocrine therapy that may provide potential biomarkers for individualized treatment of breast cancer. Keywords: PGx-eQTL, Breast cancer, Endocrine therapy, Aromatase inhibitor, GWAS, Pharmacogenomics, Androgen receptor |
| ArticleNumber | 111 |
| Audience | Academic |
| Author | Li, Hu Liu, Duan Zhang, Cheng Nguyen, Thanh Thanh. L. Wei, Lixuan Weinshilboum, Richard M. Wang, Liewei Gao, Huanyao Indulkar, Shreya Ingle, James N. Ho, Ming-Fen |
| Author_xml | – sequence: 1 givenname: Huanyao surname: Gao fullname: Gao, Huanyao organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 2 givenname: Lixuan surname: Wei fullname: Wei, Lixuan organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 3 givenname: Shreya surname: Indulkar fullname: Indulkar, Shreya organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 4 givenname: Thanh Thanh. L. surname: Nguyen fullname: Nguyen, Thanh Thanh. L. organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 5 givenname: Duan surname: Liu fullname: Liu, Duan organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 6 givenname: Ming-Fen surname: Ho fullname: Ho, Ming-Fen organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 7 givenname: Cheng surname: Zhang fullname: Zhang, Cheng organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 8 givenname: Hu surname: Li fullname: Li, Hu organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 9 givenname: Richard M. surname: Weinshilboum fullname: Weinshilboum, Richard M. organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic – sequence: 10 givenname: James N. surname: Ingle fullname: Ingle, James N. organization: Department of Oncology, Mayo Clinic – sequence: 11 givenname: Liewei surname: Wang fullname: Wang, Liewei email: Wang.Liewei@mayo.edu organization: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38965614$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Ul1rFTEQXaRiP_QP-CABX3zZmmST_fBFLkXbQkEQBd9CNpnszWU32Sa5xf4Jf7PZ3tr2ikgeksycOcOZOcfFgfMOiuI1waeEtPX7SCrM2xJTVuL8JyV9VhwRVvOSM_rj4Mn7sDiOcYMxaVrevigOq7areU3YUfFr5XTwAzgUQMGcfCgn0FYm0GheyzBJtWT9ZBWCn3OAGK136HorXbJJJnsDKAVpExq9sh-QnebRqhz3LiLjA-oDyJiQkk5ByE3inDO5xqPV1zLJMECybkBpDUHOty-L50aOEV7d3yfF98-fvp1dlFdfzi_PVlel4rxLpWYYGs1p33ayxpIrw7LUTrGqZz1RRkpdYw0Uaw6kkw1umr7XSlVEc0MUrk6Kyx2v9nIj5mAnGW6Fl1bcBXwYhAzJqhEE7nDddFRXPekZpazVpgbDTKVYy4yhmevjjmve9nl2ClweyLhHup9xdi0GfyMIoTRvp8kM7-4Zgr_eQkxislHBOEoHfhtFhZsak47wpdnbv6Abvw0uz2pBdZQ2NWkeUYPMCqwzPjdWC6lYtdkGrKlaklGn_0DloyGvO3vN2BzfK3jzVOmDxD92ygC6A6jgYwxgHiAEi8WzYudZkT0r7jwrFknVrihmsBsgPEr6T9VvyonxHA |
| Cites_doi | 10.1158/2159-8290.CD-13-0038 10.1056/NEJM195810022591404 10.1200/JCO.2009.27.3730 10.1093/bioinformatics/bts163 10.1016/j.molcel.2010.05.004 10.1038/s12276-020-0380-6 10.1158/0008-5472.CAN-16-0298 10.1093/bioinformatics/btp616 10.1210/me.2014-1147 10.1158/1078-0432.CCR-20-1693 10.1158/1535-7163.MCT-19-0508 10.1006/bbrc.2000.2991 10.1016/j.mito.2021.02.005 10.1093/nar/gkz790 10.1093/nar/gkac1045 10.1200/JCO.2010.28.5064 10.1038/modpathol.2011.54 10.1186/s13742-015-0047-8 10.3389/fgene.2018.00493 10.3389/fnagi.2018.00124 10.1158/0008-5472.CAN-16-1371 10.1038/s41380-021-01274-z 10.1158/0008-5472.CAN-08-0405 10.1038/nprot.2017.124 10.1371/journal.pone.0197827 10.1038/nature12508 10.1158/1078-0432.CCR-12-1773 10.1074/jbc.M406543200 10.1677/ERC-09-0257 10.1038/s41571-021-00521-0 10.1093/nar/gkac1010 10.1128/MCB.25.7.2808-2818.2005 10.1158/0008-5472.CAN-22-1016 10.1038/s41467-021-25624-1 10.1093/nar/gkab996 10.1158/1078-0432.CCR-19-3091 10.1007/s13238-020-00729-3 10.1038/nbt.3157 10.1007/s11357-023-00742-4 10.1101/gr.107672.110 10.1038/s41591-020-0751-5 10.3389/fgene.2020.00157 10.1371/journal.pcbi.1003118 10.1093/bioinformatics/bts635 10.1002/hep.31305 10.1172/jci.insight.137571 10.1093/bioinformatics/btu638 10.1016/j.neuron.2015.05.034 10.1038/s41556-018-0219-8 10.1001/jama.1964.03060380037009 10.1097/FPC.0000000000000415 10.1093/jnci/djt319 10.1093/bioinformatics/btu393 10.1186/1475-2867-13-105 10.1093/nar/gkr917 10.3389/fonc.2021.644857 10.1002/cac2.12382 10.1038/nchembio.2282 10.3109/13697137.2013.800039 10.1016/j.febslet.2013.10.020 10.4161/cc.6.11.4276 10.1210/en.2019-00097 10.1038/s41467-019-12194-6 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13058-024-01861-2 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1465-542X |
| EndPage | 14 |
| ExternalDocumentID | oai_doaj_org_article_0906792d3b1b42248df6ef4f3c484ff2 PMC11225427 A800147381 38965614 10_1186_s13058_024_01861_2 |
| Genre | Journal Article |
| GeographicLocations | Canada |
| GeographicLocations_xml | – name: Canada |
| GrantInformation_xml | – fundername: George M. Eisenberg Foundation – fundername: Breast Cancer Research Foundation grantid: BCRF-22–076 – fundername: Regis Foundation Mayo Clinic Center for Individualized Medicine grantid: MC1351 – fundername: Mayo Clinic Breast Cancer Specialized Program of Research Excellence Grant grantid: P50CA 116201 – fundername: Mayo Research Foundation – fundername: Mayo Clinic Schulze Cancer for Novel Therapeutics in Cancer Research – fundername: Breast Cancer Research Foundation grantid: BCRF-22-076 – fundername: NCI NIH HHS grantid: P50 CA116201 |
| GroupedDBID | --- 04C 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 7X7 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABUWG ACGFO ACGFS ACJQM ACMJI ACPRK ADBBV ADFRT ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BMSDO BPHCQ BVXVI C6C CCPQU CS3 DU5 E3Z EBD EBLON EBS EIHBH F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO ICW IHR INH INR ITC KQ8 LGEZI LOTEE NADUK NXXTH O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PUEGO RBZ ROL RPM RSV SBL SOJ TR2 U2A UKHRP WOQ AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c559t-d40e7d52b89a60a5cf44659c43b4b1cfaad60de20d5e19a7077bbdcc31d5f1c03 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001263117200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1465-542X 1465-5411 |
| IngestDate | Fri Oct 03 12:43:07 EDT 2025 Tue Nov 04 02:05:35 EST 2025 Fri Sep 05 14:57:36 EDT 2025 Sat Oct 11 13:40:44 EDT 2025 Tue Nov 11 11:03:54 EST 2025 Tue Nov 04 18:22:52 EST 2025 Mon Jul 21 06:04:06 EDT 2025 Sat Nov 29 03:59:42 EST 2025 Sat Sep 06 07:25:05 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Aromatase inhibitor GWAS PGx-eQTL Androgen receptor Endocrine therapy Breast cancer Pharmacogenomics |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c559t-d40e7d52b89a60a5cf44659c43b4b1cfaad60de20d5e19a7077bbdcc31d5f1c03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/0906792d3b1b42248df6ef4f3c484ff2 |
| PMID | 38965614 |
| PQID | 3079227617 |
| PQPubID | 2034567 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_0906792d3b1b42248df6ef4f3c484ff2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11225427 proquest_miscellaneous_3076019152 proquest_journals_3079227617 gale_infotracmisc_A800147381 gale_infotracacademiconefile_A800147381 pubmed_primary_38965614 crossref_primary_10_1186_s13058_024_01861_2 springer_journals_10_1186_s13058_024_01861_2 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-04 |
| PublicationDateYYYYMMDD | 2024-07-04 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Breast cancer research : BCR |
| PublicationTitleAbbrev | Breast Cancer Res |
| PublicationTitleAlternate | Breast Cancer Res |
| PublicationYear | 2024 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | S Heinz (1861_CR36) 2010; 38 F Yuan (1861_CR21) 2019; 47 F Hammal (1861_CR31) 2022; 50 1861_CR60 J Ernst (1861_CR34) 2017; 12 1861_CR62 1861_CR24 1861_CR22 1861_CR29 KS Ruth (1861_CR45) 2020; 26 J Arloth (1861_CR18) 2015; 86 LC Collins (1861_CR6) 2011; 24 KD Bromberg (1861_CR56) 2017; 13 JN Ingle (1861_CR1) 2016; 76 M Liu (1861_CR4) 2014; 28 AA Shabalin (1861_CR30) 2012; 28 IH Engels (1861_CR61) 2023; 25 JN Ingle (1861_CR5) 2020; 31 JN Ingle (1861_CR44) 2020; 26 L Li (1861_CR63) 2008; 68 Z Gu (1861_CR38) 2014; 30 1861_CR13 LM Mangravite (1861_CR17) 2013; 502 B Stefansson (1861_CR58) 2014; 6 MD Robinson (1861_CR28) 2009; 26 A Dobin (1861_CR26) 2013; 29 LD Ward (1861_CR33) 2011; 40 Y-S Jung (1861_CR43) 2020; 52 S Zhang (1861_CR53) 2022; 43 H Wu (1861_CR55) 2013; 587 J Baumgart (1861_CR11) 2013; 17 G Marcucci (1861_CR41) 2010; 28 S-J Park (1861_CR59) 2004; 279 BJ Kennedy (1861_CR12) 1958; 259 1861_CR47 Y-S Jung (1861_CR52) 2018; 20 K Takagi (1861_CR10) 2010; 17 S Takahashi (1861_CR54) 2000; 273 N Niu (1861_CR23) 2010; 20 V Udhane (1861_CR20) 2020; 19 1861_CR49 1861_CR48 YS Jung (1861_CR51) 2020; 73 JP Garay (1861_CR9) 2012; 2 S Chiang (1861_CR40) 2016; 76 E Sollis (1861_CR25) 2023; 51 S Dasgupta (1861_CR50) 2019; 160 H Gao (1861_CR64) 2021; 58 L Nguyen Thanh Thanh (1861_CR19) 2022; 50 JN Ingle (1861_CR3) 2010; 28 I Krop (1861_CR14) 2020; 26 1861_CR32 S Anders (1861_CR27) 2014; 31 FE Vera-Badillo (1861_CR7) 2013; 106 H Yang (1861_CR42) 2012; 18 CJ Pirozzi (1861_CR46) 2021; 18 D Liu (1861_CR16) 2021; 26 1861_CR39 1861_CR37 M Li (1861_CR57) 2020; 11 1861_CR8 JN Ingle (1861_CR2) 2013; 3 L Wei (1861_CR15) 2023; 83 J Ernst (1861_CR35) 2015; 33 |
| References_xml | – volume: 3 start-page: 812 issue: 7 year: 2013 ident: 1861_CR2 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-13-0038 – volume: 259 start-page: 673 issue: 14 year: 1958 ident: 1861_CR12 publication-title: N Engl J Med doi: 10.1056/NEJM195810022591404 – volume: 28 start-page: 2348 issue: 14 year: 2010 ident: 1861_CR41 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.27.3730 – volume: 28 start-page: 1353 issue: 10 year: 2012 ident: 1861_CR30 publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts163 – volume: 38 start-page: 576 issue: 4 year: 2010 ident: 1861_CR36 publication-title: Mol Cell doi: 10.1016/j.molcel.2010.05.004 – volume: 52 start-page: 183 issue: 2 year: 2020 ident: 1861_CR43 publication-title: Exp Mol Med doi: 10.1038/s12276-020-0380-6 – volume: 76 start-page: 7118 issue: 24 year: 2016 ident: 1861_CR40 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-0298 – volume: 2 start-page: 434 issue: 4 year: 2012 ident: 1861_CR9 publication-title: Am J Cancer Res – volume: 26 start-page: 139 issue: 1 year: 2009 ident: 1861_CR28 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btp616 – volume: 28 start-page: 1740 issue: 10 year: 2014 ident: 1861_CR4 publication-title: Mol Endocrinol doi: 10.1210/me.2014-1147 – volume: 26 start-page: 6149 issue: 23 year: 2020 ident: 1861_CR14 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-20-1693 – volume: 19 start-page: 231 issue: 1 year: 2020 ident: 1861_CR20 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-19-0508 – volume: 273 start-page: 596 issue: 2 year: 2000 ident: 1861_CR54 publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.2000.2991 – volume: 58 start-page: 83 year: 2021 ident: 1861_CR64 publication-title: Mitochondrion doi: 10.1016/j.mito.2021.02.005 – volume: 47 start-page: 10104 issue: 19 year: 2019 ident: 1861_CR21 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkz790 – volume: 50 start-page: 11635 issue: 20 year: 2022 ident: 1861_CR19 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkac1045 – volume: 28 start-page: 4674 issue: 31 year: 2010 ident: 1861_CR3 publication-title: J Clin Oncol doi: 10.1200/JCO.2010.28.5064 – volume: 24 start-page: 924 issue: 7 year: 2011 ident: 1861_CR6 publication-title: Mod Pathol doi: 10.1038/modpathol.2011.54 – ident: 1861_CR29 doi: 10.1186/s13742-015-0047-8 – ident: 1861_CR48 doi: 10.3389/fgene.2018.00493 – ident: 1861_CR49 doi: 10.3389/fnagi.2018.00124 – volume: 76 start-page: 7012 issue: 23 year: 2016 ident: 1861_CR1 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-1371 – volume: 26 start-page: 7454 issue: 12 year: 2021 ident: 1861_CR16 publication-title: Mol Psychiatry doi: 10.1038/s41380-021-01274-z – volume: 68 start-page: 7050 issue: 17 year: 2008 ident: 1861_CR63 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-0405 – volume: 12 start-page: 2478 issue: 12 year: 2017 ident: 1861_CR34 publication-title: Nat Protoc doi: 10.1038/nprot.2017.124 – ident: 1861_CR8 doi: 10.1371/journal.pone.0197827 – volume: 502 start-page: 377 issue: 7471 year: 2013 ident: 1861_CR17 publication-title: Nature doi: 10.1038/nature12508 – volume: 18 start-page: 5562 issue: 20 year: 2012 ident: 1861_CR42 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-1773 – volume: 279 start-page: 51057 issue: 49 year: 2004 ident: 1861_CR59 publication-title: J Biol Chem doi: 10.1074/jbc.M406543200 – volume: 17 start-page: 415 issue: 2 year: 2010 ident: 1861_CR10 publication-title: Endocrine-related Cancer doi: 10.1677/ERC-09-0257 – volume: 18 start-page: 645 issue: 10 year: 2021 ident: 1861_CR46 publication-title: Nat Reviews Clin Oncol doi: 10.1038/s41571-021-00521-0 – volume: 51 start-page: D977 issue: D1 year: 2023 ident: 1861_CR25 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkac1010 – volume: 25 start-page: 2808 issue: 7 year: 2023 ident: 1861_CR61 publication-title: Mol Cell Biol doi: 10.1128/MCB.25.7.2808-2818.2005 – volume: 83 start-page: 456 issue: 3 year: 2023 ident: 1861_CR15 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-22-1016 – ident: 1861_CR22 doi: 10.1038/s41467-021-25624-1 – volume: 50 start-page: D316 issue: D1 year: 2022 ident: 1861_CR31 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkab996 – volume: 26 start-page: 2986 issue: 12 year: 2020 ident: 1861_CR44 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-3091 – volume: 11 start-page: 584 issue: 8 year: 2020 ident: 1861_CR57 publication-title: Protein Cell doi: 10.1007/s13238-020-00729-3 – volume: 33 start-page: 364 issue: 4 year: 2015 ident: 1861_CR35 publication-title: Nat Biotechnol doi: 10.1038/nbt.3157 – ident: 1861_CR39 doi: 10.1007/s11357-023-00742-4 – volume: 20 start-page: 1482 issue: 11 year: 2010 ident: 1861_CR23 publication-title: Genome Res doi: 10.1101/gr.107672.110 – volume: 26 start-page: 252 issue: 2 year: 2020 ident: 1861_CR45 publication-title: Nat Med doi: 10.1038/s41591-020-0751-5 – ident: 1861_CR37 doi: 10.3389/fgene.2020.00157 – ident: 1861_CR32 doi: 10.1371/journal.pcbi.1003118 – volume: 29 start-page: 15 issue: 1 year: 2013 ident: 1861_CR26 publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts635 – volume: 73 start-page: 776 issue: 2 year: 2020 ident: 1861_CR51 publication-title: Hepatology doi: 10.1002/hep.31305 – ident: 1861_CR24 doi: 10.1172/jci.insight.137571 – volume: 31 start-page: 166 issue: 2 year: 2014 ident: 1861_CR27 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btu638 – volume: 86 start-page: 1189 issue: 5 year: 2015 ident: 1861_CR18 publication-title: Neuron doi: 10.1016/j.neuron.2015.05.034 – volume: 20 start-page: 1421 issue: 12 year: 2018 ident: 1861_CR52 publication-title: Nat Cell Biol doi: 10.1038/s41556-018-0219-8 – ident: 1861_CR13 doi: 10.1001/jama.1964.03060380037009 – volume: 31 start-page: 1 issue: 1 year: 2020 ident: 1861_CR5 publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0000000000000415 – volume: 106 start-page: djt319 issue: 1 year: 2013 ident: 1861_CR7 publication-title: JNCI J Natl Cancer Inst doi: 10.1093/jnci/djt319 – volume: 30 start-page: 2811 issue: 19 year: 2014 ident: 1861_CR38 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btu393 – ident: 1861_CR62 doi: 10.1186/1475-2867-13-105 – volume: 40 start-page: D930 issue: D1 year: 2011 ident: 1861_CR33 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkr917 – ident: 1861_CR47 doi: 10.3389/fonc.2021.644857 – volume: 43 start-page: 159 issue: 1 year: 2022 ident: 1861_CR53 publication-title: Cancer Commun doi: 10.1002/cac2.12382 – volume: 13 start-page: 317 issue: 3 year: 2017 ident: 1861_CR56 publication-title: Nat Chem Biol doi: 10.1038/nchembio.2282 – volume: 17 start-page: 48 issue: 1 year: 2013 ident: 1861_CR11 publication-title: Climacteric doi: 10.3109/13697137.2013.800039 – volume: 587 start-page: 3859 issue: 23 year: 2013 ident: 1861_CR55 publication-title: FEBS Lett doi: 10.1016/j.febslet.2013.10.020 – volume: 6 start-page: 1386 issue: 11 year: 2014 ident: 1861_CR58 publication-title: Cell Cycle doi: 10.4161/cc.6.11.4276 – volume: 160 start-page: 1811 issue: 8 year: 2019 ident: 1861_CR50 publication-title: Endocrinology doi: 10.1210/en.2019-00097 – ident: 1861_CR60 doi: 10.1038/s41467-019-12194-6 |
| SSID | ssj0017858 |
| Score | 2.4382677 |
| Snippet | Background
Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The... Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The androgen receptor... Background Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor [alpha] (ER[alpha]).... Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor [alpha] (ER[alpha]). The... BackgroundEndocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The androgen... Abstract Background Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα).... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 111 |
| SubjectTerms | Agonists Androgen receptors Androgens Antineoplastic Agents, Hormonal - pharmacology Antineoplastic Agents, Hormonal - therapeutic use Aromatase Aromatase inhibitor Benzamides Biomedical and Life Sciences Biomedicine Biosynthesis Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer Cancer Research Cancer therapies Care and treatment Cell Line, Tumor Clinical trials Dihydrotestosterone Dihydrotestosterone - pharmacology Drug delivery Drug development Endocrine therapy Estrogen Estrogen receptors Estrogens Female Gene expression Gene Expression Regulation, Neoplastic - drug effects Gene polymorphism Genes Genetic aspects Genome-Wide Association Study Genomes Genotype Globulins GWAS Hormones Humans Ligands Medical prognosis Nitriles - therapeutic use Oncology Oncology, Experimental Patients PGx-eQTL Pharmacodynamics Pharmacogenetics Pharmacogenetics - methods Pharmacogenomic Variants Pharmacogenomics Phenotypes Phenylthiohydantoin - pharmacology Phenylthiohydantoin - therapeutic use Polymorphism, Single Nucleotide Prostate Quantitative genetics Quantitative Trait Loci Receptors, Androgen - genetics Receptors, Androgen - metabolism Single nucleotide polymorphisms Single-nucleotide polymorphism Surgical Oncology Tumors Womens health |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9QwFLagIMSFpaUQKMhICA5gNXac2OGCBkTFASqEAPVmeYU5NJnOguif4Dfz7HimTRFcuMbOYufzW-zvvYfQk1bWzHEjiauoJVzoQEyoNREO_kig2tKUp_vre3F4KI-O2o95w22RaZVrmZgEtett3CPfByy2jIHTLV7NTkisGhVPV3MJjcvoSiybHXEujjYOVyw8L4fooprUnNJ10Ixs9hcgu2tJQEOBMy0bSthIMaX8_X9K6XNq6iKF8sI5alJPBzf_d2C30I1smOLJgKTb6JLvttHOpAOn_PgUP8WJKpr24LfRtQ_5RH4H_YqMyB5QiEF0-hl48CQFo4Ahi2c5LXbMA3s8tdj_zKzbDp-sdJfC20DY4limYolBq05f4uk5hjsGgxqbyJpfYhvROYeXJEov3NPjyScy8NhhQvAQR3Z6B305ePv5zTuSazwQC77MkjheeuFqZmSrm1LXNsQMbq3lleGG2qC1a0rnWelqT1stSiGMcdZW1NWB2rLaRVtd3_l7CFPpPDXOt1pbbkTQjS1t2WjHdGvAsirQ8_UPVrMhlYdKLpBs1AAHBXBQCQ6KFeh1xMCmZ0zDnS70828qr2pVtnEfjrnKUMPBGJIuND7wUFkueQjwkGcRQSoKC5hLq3PMA3xwTLulJjK6qAKspgLtjXrCIrfj5jV4VBYyC3WGnAI93jTHOyNxrvP9KvUBl7sFK61AdwfIboYEtmoTE8EWSI7APBrzuKWbfk8pyMFKZzVn8OIXa9yffdffJ_X-v4fxAF1naUUKUvI9tLWcr_xDdNX-WE4X80dpbf8Gi3JYqg priority: 102 providerName: ProQuest – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQQYgLj5ZHoCAjITiARew4scNtQVQcoEIFqt4sPyGHZre72Yr-CX4zYydZmgIHuK7tTTwezyP-5jNCT2pZMseNJK6glnChAzGh1EQ4WJFAtaWJp_vwvdjfl0dH9cehKGw1ot3HI8lkqdO2ltXLFVjbUhLwKZD-yooSMLyXwd3JeGHDwafDzdmBkKUcy2P-OG7ighJT_-_2-JxDugiWvHBimhzR3o3_m8JNdH0IPPGs15Rb6JJvt9HOrIWk-_gMP8UJCpq-sW-jqx-GE_cd9CMiHuegZRhMo19Ahk5SsQkEqngx0F5HntfjxmL_fUDVtvhkrdtUvgbGFMdrKDoMXrN5hZtzCHYMATM2ERXfYRu1bwkPSZBdGDPHswPS49RhirivEzu7jb7svf385h0Z7nAgFnKVjjiee-FKZmStq1yXNkSGttrywnBDbdDaVbnzLHelp7UWuRDGOGsL6spAbV7cQVvtvPX3EKbSeWqcr7W23IigK5vbvNKO6dpA5JSh5-OyqkVP1aFSiiMr1UtegeRVkrxiGXodV37TM9Jspx_my69q2LUqr-N3NuYKQw2HYEe6UPnAQ2G55CHAnzyLeqOiMQBZWj3UNMALR1otNZMxBRUQFWVod9ITNrGdNo-apwYjslJgfmvGBMSYGXq8aY4jIzCu9fN16gMpdQ1RWIbu9oq6mRLEolUkes2QnKjwZM7Tlrb5lijGIQpnJWfw4BejJv96r78L9f6_dX-ArrG0GQTJ-S7a6pZr_xBdsadds1o-Srv6JxebTOo priority: 102 providerName: Springer Nature |
| Title | Androgen receptor-mediated pharmacogenomic expression quantitative trait loci: implications for breast cancer response to AR-targeting therapy |
| URI | https://link.springer.com/article/10.1186/s13058-024-01861-2 https://www.ncbi.nlm.nih.gov/pubmed/38965614 https://www.proquest.com/docview/3079227617 https://www.proquest.com/docview/3076019152 https://pubmed.ncbi.nlm.nih.gov/PMC11225427 https://doaj.org/article/0906792d3b1b42248df6ef4f3c484ff2 |
| Volume | 26 |
| WOSCitedRecordID | wos001263117200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: RBZ dateStart: 19990101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: DOA dateStart: 20000101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: PIMPY dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1465-542X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017858 issn: 1465-542X databaseCode: RSV dateStart: 19991201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLZgIMQLgo1LYFRGQvAA1hLHiR3eOrQJJFZVBabyZPkq8rC09ILYn-A3c-ykpRlCvPASKbGj2D7H5xJ__ozQ80oU1DItiM0zQxhXnmhfKMItSMRnymSRp_v8Ax-NxHRajXeO-gqYsJYeuB24o7QKvzqozXWmGfgbYX3pPPO5YYJ5H61vyqtNMtWtH3BRiM0WGVEeLcFSF4KAP4LUWZQZoT03FNn6_7TJO07pKmDyyqppdEand9GdLorEw7b199A11-yjg2EDGfTFJX6BI64z_jDfR7fOuuXzA_QzwBdnoDIY7JybQ7pN4s4RiDrxvOOwDqStF7XB7kcHkW3wt7Vq4l40sIw4nCmxwuAC6ze43oGjY4h-sQ4Q9xU2QZUW8JGIv4V3Zng4IS3oHPqD201fl_fR59OTT2_fke5ABmIg8VgRy1LHbUG1qFSZqsL4QLdWGZZrpjPjlbJlah1NbeGySvGUc62tMXlmC5-ZNH-A9ppZ4x4hnAnrMm1dpZRhmntVmtSkpbJUVRrCoAS92shHzlveDRnzFVHKVpoSpCmjNCVN0HEQ4bZm4MyOD0CTZKdJ8l-alKCXQQFkmNkwlkZ1GxSgwYEjSw5FyCc5hDgJOuzVhBlp-sUbFZKdRVhKsKUVpRwCxgQ92xaHNwPKrXGzdawD-XEFIVWCHrYat-0SBJZlYG1NkOjpYq_P_ZKm_hr5wiGkpgWj8OHXG7X93a6_D-rj_zGoT9BtGqcdJyk7RHurxdo9RTfN91W9XAzQdT7l8SoG6MbxyWg8GcSJDHfj92fjL3A3-Xj-C2nGTs8 |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLZKQcCFpWUZKGAklgNYjT1O7CAhNCxVq04rhArqzXgLzKHJdCYF5k_wU_iNPDvJtFMEtx64xo4d22-Nv_ceQo9ymTLHjSSuTy3hQhfEFKkmwsGJFFRbGvN0fxqK3V25v5-_X0K_uliYAKvsZGIU1K6y4R_5OtBizhg43eLV-JCEqlHhdrUrodGQxbaffQeXbfpy6y2c72PGNt7tvdkkbVUBYsF6ronjiRcuZUbmOkt0aouQMyy3vG-4obbQ2mWJ8yxxqae5FokQxjhr-9SlBbVJH8Y9h86DHBfB2RP7cwcvFLqXTTRTSlJOaRekI7P1KeiKVBLQiOC8y4wStqAIY72AP7XCCbV4GrJ56t42qsONq__bRl5DV1rDGw8aTrmOlny5glYHpa6rgxl-giMUNt4xrKCLOy3iYBX9DIjPCrgMg2rw47qakBhsA4Y6Hrdpv0Oe24ORxf5Hiyou8eGRLmP4HigTHMpw1BishtELPDqB4MfgMGATogJqbAP3TWCSCFmGdyo8-EAanD4cAG7i5GY30Mcz2aSbaLmsSn8bYSqdp8b5XGvLjSh0ZhObZNoxnRuwHHvoWUdQatykKlHRxZOZashPAfmpSH6K9dDrQHPzniHNeHxQTb6oVmqpJA__GZnrG2o4GHvSFZkveNG3XPKigEGeBopVQRjCXlrdxnTAB4e0YmoggwsuwCrsobWFniDE7GJzR6yqFaJTdUypPfRw3hzeDMDA0ldHsU8GXgpYoT10q2GR-ZLAFs9CotsekgvMs7DmxZZy9DWmWAcvhKWcwcTPOz47_q6_b-qdfy_jAbq0ubczVMOt3e276DKL0kCQhK-h5Xpy5O-hC_ZbPZpO7ke5gtHns-a_32zEt-A |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLbQQBMvXDYYgQFGQvAA1uLEiR3eyqUCMaqJy7Q3y1fIw9LSpoj9CX4zx05amgEPiNfabuKTc42_8wWhh5UoMsu0IDanhjCuPNG-UIRbeCKeKkMjT_fxIZ9MxMlJdbTRxR_R7qsjya6nIbA0Ne3BzPrOxEV5sADPWwgC8QVKYVFSAk74IgtA-lCvfzhenyNwUYhVq8wf1w3CUWTt_903bwSn88DJc6enMSiNr_7_dq6hK31CikedBl1HF1yzg3ZHDRTjp2f4EY4Q0fjufQdtv-tP4nfRj4CEnIL2YXCZbgaVO4lNKJDA4llPhx34X09rg933Hm3b4K9L1cS2NnCyOHyeosUQTetnuN5AtmNIpLEOaPkWm6CVc7hIhPLCmikevScdfh22i7v-sbMb6NP41ccXr0n_bQdioIZpiWWp47bItKhUmarC-MDcVhmWa6ap8UrZMrUuS23haKV4yrnW1pic2sJTk-Y30VYzbdwthKmwjmrrKqUM09yr0qQmLZXNVKUho0rQk9UjlrOOwkPG0keUspO8BMnLKHmZJeh50IL1zEC_HX-Yzj_L3pplWoX3b5nNNdUMkiBhfek887lhgnkPf_I46JAMTgJkaVTf6wA3HOi25EiE0pRDtpSg_cFMMG4zHF5poeydy0KCW66yjEPumaAH6-GwMgDmGjddxjlQaleQnSVor1Pa9ZYgRy0DAWyCxECdB3sejjT1l0g9Dtl5VrAMLvx0pdW_7uvvQr39b9Pvo-2jl2N5-Gby9g66nEW74CRl-2irnS_dXXTJfGvrxfxeNPafCltYsg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Androgen+receptor-mediated+pharmacogenomic+expression+quantitative+trait+loci%3A+implications+for+breast+cancer+response+to+AR-targeting+therapy&rft.jtitle=Breast+cancer+research+%3A+BCR&rft.au=Gao%2C+Huanyao&rft.au=Wei%2C+Lixuan&rft.au=Indulkar%2C+Shreya&rft.au=Nguyen%2C+Thanh+Thanh.+L.&rft.date=2024-07-04&rft.pub=BioMed+Central&rft.issn=1465-5411&rft.eissn=1465-542X&rft.volume=26&rft_id=info:doi/10.1186%2Fs13058-024-01861-2&rft_id=info%3Apmid%2F38965614&rft.externalDocID=PMC11225427 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-542X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-542X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-542X&client=summon |